Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
synthetic estrogen |
| gptkbp:administeredBy |
gptkb:medroxyprogesterone_acetate
gptkb:cyproterone_acetate norethisterone enantate |
| gptkbp:affiliatedWith |
estrogen ester
|
| gptkbp:ATCCode |
G03CA03
|
| gptkbp:brand |
Delestrogen
Progynova Cyclo-Progynova |
| gptkbp:CASNumber |
979-32-8
|
| gptkbp:chemicalFormula |
C23H32O3
|
| gptkbp:contraindication |
gptkb:cancer
undiagnosed vaginal bleeding active thromboembolic disorders |
| gptkbp:discoveredBy |
gptkb:Schering_AG
|
| gptkbp:eliminationHalfLife |
3-7 days (intramuscular)
|
| gptkbp:foundIn |
combined injectable contraceptives
feminizing hormone therapy regimens |
| https://www.w3.org/2000/01/rdf-schema#label |
estradiol valerate
|
| gptkbp:KEGGID |
D07910
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
1954
|
| gptkbp:MeSH_ID |
D004967
|
| gptkbp:metabolism |
gptkb:estradiol
valeric acid |
| gptkbp:molecularWeight |
356.5 g/mol
|
| gptkbp:pregnancyCategory |
X (contraindicated)
|
| gptkbp:PubChem_CID |
30323
CHEMBL1200706 DB00977 |
| gptkbp:routeOfAdministration |
oral
intramuscular injection |
| gptkbp:sideEffect |
nausea
headache breast tenderness increased risk of blood clots fluid retention |
| gptkbp:synonym |
E2V
estradiol 17β-valerate |
| gptkbp:UNII |
OKG364O896
|
| gptkbp:usedFor |
prostate cancer
menopausal symptoms contraception hormone replacement therapy transgender hormone therapy |
| gptkbp:bfsParent |
gptkb:Climodien
|
| gptkbp:bfsLayer |
7
|